RxDoctor Payments Data

Miguel Flores, MD

Psychiatry · Miami, FLNPI 1639167513

Payments from drug & device makers

$379,636in general payments, 2019–2025

Across 223 payments — averaging $1702.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$171K
  • Otsuka America Pharmaceutical, Inc.$57K
  • Janssen Research & Development, LLC$52K
  • Teva Pharmaceuticals USA, Inc.$33K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$31K
  • Avanir Pharmaceuticals, Inc.$28K
  • plus $10K from 4 others

What the payments were for

  • Speaking & faculty fees$171,76898%
  • Travel & lodging$4560%
  • Food & beverage$3,7792%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$379,636 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$92,158
Medicare patients
355
Services billed
810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole90$136,566
VraylarCariprazine Hcl54$85,280
Invega SustennaPaliperidone Palmitate14$53,255
TrintellixVortioxetine Hydrobromide36$17,410
Aripiprazole367$15,527
Temazepam1,432$11,061
Quetiapine Fumarate549$9,450
VyvanseLisdexamfetamine Dimesylate20$8,276
Bupropion XlBupropion Hcl461$7,305
Lurasidone Hcl39$5,868
Venlafaxine Hcl ErVenlafaxine Hcl135$5,727
Alprazolam986$5,416
Meprobamate11$5,296
Escitalopram Oxalate767$5,036
Clonazepam628$4,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$56,615$136,56690 claims
AbbVieVraylar$170,512$85,28054 claims
Johnson & JohnsonInvega Sustenna$216$53,25514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →